One-Shot Intravesical Instillation of the Mucous Adhesive Anticancer Agent Hydroxypropylcellulose- Doxorubicin for the Treatment of Superficial Bladder Carcinoma Is Sufficient to Determine Antitumor Effects

1993 ◽  
Vol 24 (1) ◽  
pp. 62-65
Author(s):  
Kousuke Ueda ◽  
Hiroshi Sakagami ◽  
Yasuhiko Masui ◽  
Takehiko Okamura ◽  
Kazuo Ohtaguro
Keyword(s):  
Bladder Carcinoma ◽  
Anticancer Agent ◽  
Intravesical Instillation ◽  
Antitumor Effects ◽  
Superficial Bladder Carcinoma

scholarly journals Bladder perforation after immediate postoperative intravesical instillation of mitomycin C

2013 ◽  
Vol 4 (1) ◽  
pp. 1 ◽  
Author(s):  
Darwin Lim ◽  
Jonathan I. Izawa ◽  
Paul Middlebrook ◽  
Joseph L. Chin
Keyword(s):  
Intensive Care ◽  
Single Dose ◽  
Mitomycin C ◽  
Male Patient ◽  
Transurethral Resection ◽  
Bladder Carcinoma ◽  
Adjunctive Therapy ◽  
Intravesical Instillation ◽  
Recurrence Rates ◽  
Superficial Bladder Carcinoma

Intravesical chemotherapy after transurethral resection of a bladdertumour (TURBT) has been observed to significantly decreaserecurrence rates compared to TURBT alone. Though immediatepostoperative intravesical treatment with chemotherapeutic agentsafter transurethral resection for superficial bladder carcinoma isgenerally considered a safe and effective adjunctive therapy indecreasing recurrence rates, its instillation is not always completelyinnocuous. Lately, a more serious complication of bladderperforation associated with immediate instillation of intravesicalmitomycin C (MMC) after TURBT was reported. We reportour own experience of a male patient with bladder perforationafter an early instillation of a single dose of MMC. In this case,systemic toxicity occurred which required intensive care aftersurgical repair.

Long-Term Follow-Up of Cytostatic Intravesical Instillation in Patients with Superficial Bladder Carcinoma

1997 ◽  
Vol 31 (2) ◽  
pp. 153-159 ◽  
Author(s):  
Hartwig Schwaibold ◽  
Uwe Pichlmeier ◽  
Hans-Jörg Klingenberger ◽  
Hartwig Huland
Keyword(s):  
Bladder Carcinoma ◽  
Intravesical Instillation ◽  
Superficial Bladder Carcinoma ◽  
Long Term Follow Up

Cytostatic Intravesical Instillation in Patients with Superficial Bladder Carcinoma for the Prevention of Recurrent Tumors

1988 ◽  
Vol 14 (3) ◽  
pp. 202-206 ◽  
Author(s):  
H. Huland ◽  
G. Klöppel ◽  
U. Otto ◽  
I. Feddersen ◽  
W. Brachmann ◽  
...  
Keyword(s):  
Bladder Carcinoma ◽  
Intravesical Instillation ◽  
Recurrent Tumors ◽  
Superficial Bladder Carcinoma

Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection

2004 ◽  
Vol 94 (3) ◽  
pp. 317-321 ◽  
Author(s):  
Kenji Mitsumori ◽  
Norihiko Tsuchiya ◽  
Tomonori Habuchi ◽  
Zhenhua Li ◽  
Toshiya Akao ◽  
...  
Keyword(s):  
Transurethral Resection ◽  
Large Dose ◽  
Bladder Carcinoma ◽  
Intravesical Instillation ◽  
Superficial Bladder Carcinoma

scholarly journals INTRAVESICAL INSTILLATION OF BACILLUS CALMETTE-GUERIN FOR SUPERFICIAL BLADDER CARCINOMA

1991 ◽  
Vol 82 (2) ◽  
pp. 290-296 ◽  
Author(s):  
Noboru Yabusaki ◽  
Hideki Komatsu ◽  
Kiichirou Tago ◽  
Yutaka Yamada ◽  
Akira Ueno
Keyword(s):  
Bladder Carcinoma ◽  
Intravesical Instillation ◽  
Bacillus Calmette Guerin ◽  
Superficial Bladder Carcinoma

scholarly journals BCG Immunotherapy for Bladder Carcinoma

KYAMC Journal ◽  
2017 ◽  
Vol 8 (1) ◽  
pp. 56-60
Author(s):  
Ashraf Uddin Mallik ◽  
Md Mostafizur Rahman ◽  
Horobilash Halder
Keyword(s):  
Bladder Cancer ◽  
Bladder Carcinoma ◽  
Anticancer Agent ◽  
Superficial Bladder Cancer ◽  
Bacillus Calmette Guerin ◽  
T Helper ◽  
First Line ◽  
Intravesical Bcg ◽  
Superficial Bladder Carcinoma

Purpose: We reviewed the literatures to see history, regimen of BCG and how BCG become a standard therapy for bladder carcinoma.Materials and Methods: We reviewed the previous literature describing the bacillus Calmette-Guerin (BCG) vaccine as an anticancer agent and its success as the most effective immunotherapy used against human bladder cancer and its adverse effects.Results: The association between tuberculosis and carcinoma is well established, It demonstrate that Bacillus Calmette-Guerin have immunological reactivity, inhibiting the tumor growth and progression in experimental animal models, led to clinical trials showing that intravesical Bacillus Calmette-Guerin eradicate and prevent recurrence and progression of superficial bladder carcinoma The exact mechanism of action of intravesical BCG instillation is still under investigation. However, it appears that BCG is mediated by the local immune response, mainly through T-helper cell response. It reduces the recurrence rate by an average of 40% and progression by more than 20% in papillary tumors, Carcinoma-in-situ over the patients without BCG therapy.Conclusions: For the last 45 yrs Bacillus Calmette- Guerin therapy has remained first line intravesical immunotherapy for superficial bladder cancer, an outstanding example of successful immunotherapy.KYAMC Journal Vol. 8, No.-1, Jul 2017, Page 56-60

Results at 5 years of intra vesical gemcitabine (G) single agent as adjuvant chemotheray in superficial transitional cell carcinoma (TCC) of the bladder

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e16087-e16087
Author(s):  
F. Smaili ◽  
A. Bounedjar ◽  
R. Ferhat ◽  
K. Bouzid
Keyword(s):  
Bladder Carcinoma ◽  
Single Agent ◽  
Transitional Cell ◽  
Intravesical Instillation ◽  
Phase Iii ◽  
Intravesical Therapy ◽  
Superficial Bladder Carcinoma ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasion

e16087 Background: Systemic intravenous gemcitabine is usually used in advanced bladder carcinoma, intravesical G is a novel treatment approach for TCC. In this study we evaluate the efficacy of intravesical Gemcitabine in patients (pts) with superficial bladder carcinoma. Methods: From February 2003 to June 2004, 60 pts (57M/3F) were enrolled in the study (M/F = 57/3). The median age was 59,5 years old (24–84). Nine pts had a carcinoma in situ (Cis) and 51 had pT1 lesions. Three weeks after a total transurethral resection (TUR), patients receive intravesical instillation of 2000 mg G every week for 6 weeks, than every month for six months. They received a total of 720 instillations, Follow up was with cystoscopy and urine cytology every six months. Results: At a median follow-up time 60 months, all patients were evaluable for tumor response: 23(38, 3%) patient had a persistant complete remission after treatment, 26 patients (43,3%) had a superficial relapse of TCC, six patients (10%) had progressive disease: four with muscle invasion and two with distant metastasis. Conclusions: Intravesical therapy with gemcitabine is active and well tolerated treatment in patients with superficial TCC carcinoma of the bladder. A phase III trial comparing GEM with intravesical BCG or MMC is warranted No significant financial relationships to disclose.

Thin-Section CT with Air Insufflation Technique for Bladder Carcinoma: CT Findings of Superficial Bladder Carcinoma

1994 ◽  
Vol 30 (2) ◽  
pp. 347
Author(s):  
Mi Hye Kim ◽  
Kyung Sub Shinn ◽  
Hyun Kim ◽  
Ha Hun Song ◽  
Si Won Kang ◽  
...  
Keyword(s):  
Thin Section ◽  
Bladder Carcinoma ◽  
Ct Findings ◽  
Superficial Bladder Carcinoma ◽  
Air Insufflation
Sign in / Sign up

Export Citation Format

Share Document